MX2016017388A - Metodos para tratar o aliviar la migraña. - Google Patents
Metodos para tratar o aliviar la migraña.Info
- Publication number
- MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- methods
- treating
- administering
- partial agonist
- Prior art date
Links
- 206010027599 migraine Diseases 0.000 title abstract 7
- 208000019695 Migraine disease Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 3
- 239000004031 partial agonist Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000001054 cortical effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010049714 Abdominal migraine Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000005056 Ophthalmoplegic Migraine Diseases 0.000 abstract 1
- 206010052784 Retinal migraine Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000001667 episodic effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015727P | 2014-06-23 | 2014-06-23 | |
| US201562109386P | 2015-01-29 | 2015-01-29 | |
| PCT/US2015/037177 WO2015200322A1 (en) | 2014-06-23 | 2015-06-23 | Methods of treating or ameliorating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017388A true MX2016017388A (es) | 2018-02-19 |
Family
ID=54938737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017388A MX2016017388A (es) | 2014-06-23 | 2015-06-23 | Metodos para tratar o aliviar la migraña. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3157943A4 (https=) |
| JP (2) | JP6688748B2 (https=) |
| KR (1) | KR20170018072A (https=) |
| CN (1) | CN106661085A (https=) |
| AU (1) | AU2015280108B2 (https=) |
| BR (1) | BR112016030375A8 (https=) |
| CA (1) | CA2953170A1 (https=) |
| MX (1) | MX2016017388A (https=) |
| RU (1) | RU2721401C2 (https=) |
| WO (1) | WO2015200322A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7476229B2 (ja) * | 2019-04-15 | 2024-04-30 | フェリン・ファーマシューティカルズ・インコーポレイテッド | 片頭痛の治療 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006468A1 (en) * | 1993-09-01 | 1995-03-09 | Smithkline Beecham Corporation | Method for treating migraine headaches |
| DE60131032T2 (de) * | 2000-08-25 | 2008-08-14 | Research Corp. Technologies, Inc., Tucson | Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne |
| EP1337559A2 (en) * | 2000-11-17 | 2003-08-27 | Bayer Ag | Regulation of human nmda receptor |
| ES2381091T3 (es) * | 2003-03-06 | 2012-05-23 | Botulinum Toxin Research Associates, Inc. | Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica |
| NZ590793A (en) * | 2008-07-23 | 2012-07-27 | Kyowa Hakko Kirin Co Ltd | Therapeutic agent for migraine |
| WO2011003064A2 (en) * | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
| CN105037492A (zh) * | 2010-02-11 | 2015-11-11 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| US20140107037A1 (en) * | 2011-04-27 | 2014-04-17 | Northwestern University | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| US20150253305A1 (en) * | 2012-10-12 | 2015-09-10 | Northwestern University | Methods of identifying compounds for treating depression and other related diseases |
-
2015
- 2015-06-23 CN CN201580033913.6A patent/CN106661085A/zh active Pending
- 2015-06-23 WO PCT/US2015/037177 patent/WO2015200322A1/en not_active Ceased
- 2015-06-23 CA CA2953170A patent/CA2953170A1/en not_active Abandoned
- 2015-06-23 JP JP2016575106A patent/JP6688748B2/ja active Active
- 2015-06-23 AU AU2015280108A patent/AU2015280108B2/en not_active Ceased
- 2015-06-23 BR BR112016030375A patent/BR112016030375A8/pt not_active IP Right Cessation
- 2015-06-23 EP EP15811633.5A patent/EP3157943A4/en not_active Withdrawn
- 2015-06-23 MX MX2016017388A patent/MX2016017388A/es unknown
- 2015-06-23 KR KR1020177001848A patent/KR20170018072A/ko not_active Ceased
- 2015-06-23 RU RU2017101410A patent/RU2721401C2/ru active
-
2020
- 2020-04-06 JP JP2020068289A patent/JP2020114863A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016030375A2 (pt) | 2017-08-15 |
| JP2017519778A (ja) | 2017-07-20 |
| CA2953170A1 (en) | 2015-12-30 |
| RU2017101410A3 (https=) | 2019-01-21 |
| CN106661085A (zh) | 2017-05-10 |
| AU2015280108B2 (en) | 2019-11-28 |
| BR112016030375A8 (pt) | 2021-07-13 |
| KR20170018072A (ko) | 2017-02-15 |
| RU2017101410A (ru) | 2018-07-24 |
| WO2015200322A1 (en) | 2015-12-30 |
| JP2020114863A (ja) | 2020-07-30 |
| AU2015280108A1 (en) | 2017-01-19 |
| EP3157943A4 (en) | 2018-01-24 |
| RU2721401C2 (ru) | 2020-05-19 |
| EP3157943A1 (en) | 2017-04-26 |
| JP6688748B2 (ja) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| DOP2017000268A (es) | Metodos y kits para tratar depresion | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX2016008108A (es) | Angiotensina ii sola o en combinacion para el tratamiento de hipotension. | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX391926B (es) | Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| MX2016017388A (es) | Metodos para tratar o aliviar la migraña. |